Co-Diagnostics Inc (CODX)
NASDAQ:CODX
CODX Stock Chart & Stats
$0.26
-$0.07(-8.42%)
At close: 4:00 PM EST
$0.26
-$0.07(-8.42%)
Day’s Range― - ―
52-Week Range$1.35 - $46.50
Previous CloseN/A
Volume146.43K
Average Volume (3M)10.09M
Market Cap
$5.01M
Enterprise Value-$9.04M
Total Cash (Recent Filing)$11.88M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.35
Shares Outstanding3,602,465
10 Day Avg. Volume1,334,715
30 Day Avg. Volume10,088,102
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.81
Enterprise Value/Revenue-21.62
Enterprise Value/Gross Profit-22.60
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$5.00Price Target Upside1823.08% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-12.15
Revenue Forecast (FY)$576.20K
Bulls Say, Bears Say
Bulls Say
Partnerships And Market ExpansionJoint ventures and international expansion targeting tuberculosis, HPV, and other high-need markets could create new revenue streams and broaden the device's addressable market.
Product PerformancePCR Pro offers laboratory-grade diagnostic performance in a compact, low-cost format suitable for point-of-care settings, which could increase uptake in clinics and decentralized labs.
Technology PotentialAnalyst maintains a positive view on the Co‑Primer technology, noting its potential to improve sensitivity and specificity for PCR-based diagnostics and support commercial adoption of PCR Pro.
Bears Say
Capital AccessPotential delisting could make it harder to access capital markets needed to fund operations and growth, increasing the company's financing risk.
Listing RiskAnalyst highlights the risk of delisting as a primary concern, which could drive share volatility and deter potential investors.
Regulatory And Listing UncertaintyHold ratings reflect that listing and regulatory uncertainties are outweighing the company's product strengths in investor assessments, limiting upside until clarity is achieved.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $1.35 and its highest was $46.50 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $5.01M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is May 07, 2026 which is in 27 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Mar 31, 2026. The company reported -$16.35 earnings per share for the quarter, missing the consensus estimate of -$3.6 by -$12.75.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 3,602,465 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$16.35 in its last earnings report, missing expectations of -$3.6. Following the earnings report the stock price went down -12.903%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
CODX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed clear strategic and operational progress — NASDAQ relisting, CoSara manufacturing license and regional expansion, CoMira JV advancement, strengthened IP, progress in clinical programs (1,200+ enrollments) and AI development — but these positives are offset by significant financial headwinds: an ~84.6% revenue decline driven by lower grant income, a large $18.9M noncash impairment that increased operating expenses, a widened GAAP net loss ($46.9M) and a ~60% reduction in cash to $11.9M. Management highlighted cost discipline and improved adjusted EBITDA excluding impairment, and articulated near-term commercialization paths (notably TB in India expected by Q3 2026), yet the company faces continued cash burn and will need to secure additional financing or strategic transactions to execute growth plans. Overall, the call signals meaningful operational milestones but material financial and execution risks remain.View all CODX earnings summariesCODX Stock 12 Month Forecast
Average Price Target
$5.00
▲(1823.08% Upside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Ownership Overview
Currently, No data available
---